Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congressional obstacle for Reagan-Udall Foundation

Executive Summary

Rep. Rosa DeLauro (D-Conn.) is asking FDA to stop all activities related to the creation of the Reagan-Udall Foundation until policies are established that safeguard against industry influence. The foundation was established by the FDA Amendments Act to advance the agency's Critical Path initiative and identify unmet scientific needs, but is currently unfunded. In a letter to FDA Nov. 1, DeLauro expresses concern that Critical Path activities, including those by the Reagan-Udall Foundation, could lead to the "approval of drugs and devices based on lower standards for safety and efficacy, and without appropriately designed clinical trials." The congresswoman further suggests that funds for the foundation be withheld until other FDA initiatives are fully funded...

You may also be interested in...



With Federal Dollars Scarce, FDA May Fundraise For Regulatory Science Initiative

Industry and other federal agencies could end up helping fund Commissioner Margaret Hamburg’s Regulatory Science Initiative, as FDA searches for money outside the appropriations process.

FDA Coffers Fill With Funds, But No Money For Reagan-Udall Or Lab Closures

FDA enters 2008 with the financial wherewithal to go full speed ahead in hiring and establishing the safety programs authorized by the FDA Amendments Act, following President Bush's signing of an omnibus fiscal 2008 appropriations package on Dec. 26

McClellan back at FDA

Brookings Institution's Engelberg Center for Healthcare Reform Director Mark McClellan returns to his FDA bailiwick as chairman of the Reagan-Udall Foundation. The former FDA commissioner will lead the private organization established by the FDA Amendments Act to advance the agency's Critical Path initiative and identify unmet scientific needs. Other Reagan-Udall board members announced Nov. 16 include representatives from Genzyme and Johnson & Johnson. House Agriculture-FDA Appropriations Chairwoman Rosa DeLauro, D-Conn., has requested FDA stop activities related to the creation of the foundation until the agency addresses issues of industry influence (1"The Tan Sheet" Nov. 12, 2007, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel